— Know what they know.
/
Not Investment Advice

PODD

NASDAQ · USD
Insulet Corp.
Healthcare · Medical - Devices
CEO Ashley McEvoy Employees 5,400 R&D / revenue 11.1%
Last price
$141.10+1.68%last session
Market cap
$9.8B
P/E (TTM)
26.3x
From 52w high
−60.2%
From 52w low
+11.6%
1-year return
−55.4%
RSI 14 · vs SMA200
55.6 · −24.0%
IS score
70.9/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

PODD   SPY   XLV (sector ETF) · weekly closes
406080100120Jan 26Apr 26Jul 26Oct 26XLV 124SPY 116PODD 45

Score DNA

Each bar is a 0-100 score within the scored universe
71
Profitability
78
Growth
43
Value
100
Momentum
100
Risk (safety)
86
Quality
82
Balance sheet
73
Earnings quality

Flags

Strengths
✓ Piotroski 8+✓ Insider buying✓ Congress buying
Warnings
None of the computed warning flags fires for PODD (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Narrow, Cost AdvantagePiotroski 9 / 9Altman Z 5.8Beta 1.084 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
2
$0.56M bought
Form 144 notices (12m): 4, $2.9M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
3
Last disclosed purchase 2026-09-11
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
−56
91 new holders, 138 closed
729 filers hold 103.9% · 330 added, 251 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+78
548 funds adding shares
470 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
61.7%
20-day avg 46.0%, 50-day avg 49.2%
Latest 15.7 pp over its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$2.7B
Revenue growth YoY+30.7%
Gross margin71.6%
Operating income$473.8M
Operating margin17.5%
Net income$247.1M
Net margin9.1%
EPS (diluted)$3.48
Cash flow
Operating cash flow$569.3M
Capital expenditure$191.6M
Free cash flow$377.7M
FCF conversion (FCF / OCF)66.3%
Stock-based compensation$62.7M
FCF less SBC$315.0M
Buybacks$59.6M
Dividends$0
Balance sheet & returns
Cash & short-term investments$716.1M
Total debt$1.0B
Net debt$285.8M
Shareholders' equity$1.5B
Goodwill & intangibles$168.7M
Debt / equity0.67
ROE (TTM)26.7%
ROIC (TTM)16.0%
Operating margin by fiscal year
11.5%FY20212.9%FY202213.0%FY202314.9%FY202417.5%FY2025
Revenue $1.1B (FY2021) to $2.7B (FY2025), a 25.3% CAGR.

Valuation

P/E (TTM)26.3x
EV / EBITDA15.5x
Price / sales3.20x
Price / FCF32.8x
FCF yield3.05%
Buyback yield0.61%
SBC / revenue2.6%
Price / book6.88x
Forward P/E FY202621.7x
Forward P/E FY202718.3x
Forward P/E FY202815.1x
Forward multiples divide today's price by Street EPS estimates. Street mean target $165.91 across 11 analysts last quarter is theirs, not ours.

PODD vs industry median

318 companies in Medical - Devices
Gross margin 71.1% 57.3% Operating margin 16.9% -22.8% Net margin 12.3% -23.0% ROIC 16.0% -5.0%
PODD (TTM)Industry median Asset turnover 0.96 vs industry 0.55 · financial leverage 2.23

Earnings delivery

Next report 2026-11-04 · consensus EPS $1.59
92%
beat rate, 11 of 12 quarters
+18.9%
median EPS surprise
8
longest beat streak
+77+112+87-2+18+15+29+27+9+5+19+13
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-11-02 to 2026-08-05. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
PODD Insulet Corp. $9.8B26.3x26.7%12.3%+30.7% −55.4%
GKOS Glaukos Corporation $9.7Bn/m-26.0%-9.9%+41.5% +93.2%
BIO Bio-Rad Laboratories, Inc. $9.5B42.5x3.1%57.1%+1.4% +13.2%
MASI Masimo Corporation $9.4B125.0x8.8%14.1%−14.4% +23.5%
GMED Globus Medical, Inc. $10.3B19.3x11.8%19.2%+19.7% +30.9%
ALGN Align Technology, Inc. $10.5B25.6x10.2%10.3%+4.4% —
BRKR Bruker Corporation $8.3Bn/m-3.4%-6.2%+1.6% —
SNN Smith & Nephew plc $12.2B19.0x21.7%9.8%+11.5% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-09-21Material Agreement; Financial Obligation; Exhibits
2026-09-16Officer/Director Change; Exhibits
2026-09-10Officer/Director Change
2026-08-05Earnings Release; Exhibits
2026-06-25Officer/Director Change; Regulation FD; Exhibits
2026-05-26Regulation FD; Exhibits

Context

Shares outstanding69,354,197
Free float99.6%
Institutional ownership103.9%
Beta1.08
Dividend yield0.00%
Last dividendNone on file
50 / 200-day average$140.39 / $186.49
Mid-cap Healthcare median P/E27.1x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Narrow).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where PODD sits among 61 scored companies in Medical - Devices (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasurePODDIndustry medianIndustry percentileSector median
P/E (TTM) 26.1x 25.7x
52nd		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) 0.32 1.33
13th		 1.28
Price / sales 3.2x 3.3x
47th		 3.7x
Price / book 6.9x 3.5x
75th		 3.6x
Price / tangible book 8.4x 5.7x
59th		 5.8x
Price / free cash flow 32.8x 26.8x
67th		 21.2x
Price / operating cash flow 19.1x 19.5x
44th		 17.1x
Enterprise value $10.2B $2.0B
83rd		 $2.5B
EV / sales 3.3x 3.5x
47th		 3.8x
EV / EBITDA 15.4x 18.6x
45th		 16.2x
EV / EBIT 18.3x 24.7x
30th		 23.0x
EV / free cash flow 34.2x 27.6x
58th		 24.6x
Earnings yield 3.8% -0.7%
77th		 -0.3%
FCF yield 3.0% 1.9%
60th		 1.7%
Operating cash flow yield 5.2% 3.4%
68th		 2.9%
Graham number (per share) $49.93 $42.90
59th		 $26.70

Profitability (TTM)

MeasurePODDIndustry medianIndustry percentileSector median
Gross margin 71.1% 63.7%
72nd		 65.1%
EBITDA margin 21.7% 9.3%
78th		 6.6%
Operating margin 16.9% 4.0%
82nd		 3.5%
EBIT margin 18.3% 1.4%
83rd		 2.4%
Net margin 12.3% -1.7%
82nd		 0.3%
NOPAT margin 12.8% 0.1%
77th		 2.7%
FCF margin 9.8% 3.0%
63rd		 4.3%
Operating cash flow margin 16.7% 8.5%
65th		 7.1%
R&D / revenue 11.3% 10.1%
63rd		 12.4%
SG&A / revenue 42.9% 46.6%
43rd		 37.9%
Stock comp / revenue 2.6% 3.5%
43rd		 4.5%
Effective tax rate 24.1% 21.0%
83rd		 21.0%

Returns on capital

MeasurePODDIndustry medianIndustry percentileSector median
ROE (on average equity) 26.0% -1.7%
95th		 0.8%
ROA 11.3% -1.1%
93rd		 -0.3%
ROIC 21.3% 1.1%
93rd		 5.5%
ROCE 23.1% 1.6%
95th		 2.3%
Return on tangible assets 16.8% 1.0%
97th		 1.7%
Cash ROIC (OCF / invested capital) 27.8% 7.0%
90th		 9.7%
Gross profitability (GP / assets) 68.6% 36.4%
90th		 29.9%
ROIC, 3-yr average 15.5% -1.0%
90th		 2.6%
ROIC, 5-yr average 12.5% -0.4%
80th		 3.2%
ROE, 5-yr average 20.3% -4.8%
88th		 -4.9%
Incremental ROIC -41.6% 19.9%
24th		 17.2%

Growth

MeasurePODDIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 29.4% 11.5%
86th		 10.5%
Revenue growth (QoQ) 5.3% 7.8%
35th		 7.2%
Revenue CAGR, 3 yr 27.7% 11.6%
89th		 10.7%
Revenue CAGR, 5 yr 25.1% 12.8%
83rd		 12.1%
Gross profit CAGR, 3 yr 33.6% 12.8%
90th		 10.6%
Operating income CAGR, 3 yr 82.3% 12.0%
96th		 11.7%
Net income growth (TTM YoY) 59.0% 8.7%
79th		 17.5%
Net income CAGR, 3 yr 81.4% 13.1%
95th		 11.3%
EPS growth (TTM YoY) 61.8% 7.8%
75th		 19.2%
EPS CAGR, 3 yr 82.0% 14.5%
95th		 14.0%
EPS CAGR, 5 yr —
FCF growth (TTM YoY) -23.2% 16.8%
17th		 18.6%
FCF CAGR, 3 yr —
Operating cash flow CAGR, 3 yr 49.9% 18.3%
74th		 11.9%
Book value CAGR, 3 yr 37.4% 5.2%
96th		 2.1%
Dividend CAGR, 3 yr —
Sustainable growth rate 26.0% 10.9%
89th		 12.2%

Margin history & stability

MeasurePODDIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 70.3% 64.5%
72nd		 62.6%
Operating margin, 3-yr average 16.2% 4.3%
85th		 1.0%
Net margin, 3-yr average 14.5% -5.8%
91st		 -2.6%
FCF margin, 3-yr average 12.5% 2.8%
77th		 3.2%
Revenue stability (0-1) 0.95 0.90
60th		 0.80
Earnings stability (0-1) 0.75 0.30
83rd		 0.37
Margin stability (0-1) 0.95 0.96
38th		 0.93

Liquidity (latest quarter)

MeasurePODDIndustry medianIndustry percentileSector median
Cash & short-term investments $534.9M $184.9M
77th		 $330.9M
Net cash (− = net debt) −$413.5M −$37.3M
32nd		 $8.4M
Working capital $1.1B $318.0M
80th		 $381.1M
Current ratio 2.48 3.35
37th		 3.02
Quick ratio 1.83 2.33
40th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.72 0.87
38th		 1.43
Defensive interval (days) 248 days 324 days
30th		 415 days

Leverage & solvency (latest quarter)

MeasurePODDIndustry medianIndustry percentileSector median
Total debt $948.4M $263.7M
70th		 $289.1M
Debt / equity 0.67 0.54
60th		 0.45
Net debt / equity 0.29 0.28
53rd		 −0.13
Debt / assets 30.0% 27.9%
55th		 24.4%
Debt / capital 40.0% 35.1%
60th		 31.1%
Debt / EBITDA 1.43 2.56
37th		 2.62
Net debt / EBITDA 0.62 2.08
34th		 1.42
Interest coverage (EBIT / interest) 8.8x 0.4x
79th		 2.1x
Cash interest coverage 8.1x 3.2x
75th		 3.6x
Debt payback (years of OCF) 1.9 yrs 3.4 yrs
28th		 2.7 yrs
Liabilities / assets 55.1% 49.8%
63rd		 49.8%
IS credit model rating AA — —
Implied credit spread (bps) 80 225
17th		 225

Efficiency

MeasurePODDIndustry medianIndustry percentileSector median
Asset turnover 0.92 0.60
82nd		 0.56
Fixed asset turnover 3.56 4.84
21st		 4.87
Inventory turnover 1.9 1.8
60th		 2.7
Receivables turnover 5.9 6.4
38th		 6.4
Days sales outstanding 62 days 57 days
62nd		 57 days
Days inventory outstanding 193 days 207 days
40th		 136 days
Days payables outstanding 45 days 59 days
37th		 59 days
Cash conversion cycle (days) 209 days 214 days
47th		 70 days
Capex / revenue 7.0% 3.6%
91st		 2.6%
Capex / depreciation 2.02 0.67
90th		 0.55
Operating expense ratio 54.0% 57.4%
37th		 56.5%

Cash flow & earnings quality

MeasurePODDIndustry medianIndustry percentileSector median
Operating cash flow / net income 1.36 1.65
37th		 1.61
FCF / net income 0.79 1.30
15th		 1.36
FCF / operating cash flow 58.4% 63.6%
40th		 81.2%
Capex / operating cash flow 41.6% 36.4%
60th		 18.8%
Accruals ratio -4.1% -5.2%
65th		 -5.4%
Sloan accruals ratio -7.5% -1.3%
27th		 -1.3%
Earnings quality score (0-1) 1.00 1.00
48th		 0.75

Dividends & buybacks

MeasurePODDIndustry medianIndustry percentileSector median
Dividend yield 0.0% 0.0%
0th		 0.0%
Dividend per share (TTM) $0.00 $0.00
0th		 $0.00
Payout ratio (dividends / net income) 0.0% 0.0%
0th		 0.0%
Dividends / FCF 0.0% 0.0%
0th		 0.0%
Dividend growth (YoY) —
Buyback yield 3.4% 0.0%
93rd		 0.0%
Shareholder yield (dividends + buybacks) 3.4% 0.0%
88th		 0.0%
Share count change (YoY) -1.8% 1.4%
12th		 2.0%
Buybacks, last 5 years $838.4M $0
80th		 $0

Scores & forensic checks

MeasurePODDIndustry medianIndustry percentileSector median
IS score 71 41
90th		 46
IS profitability 71 20
93rd		 22
IS growth 78 60
86th		 60
IS value 43 39
63rd		 39
IS momentum 100 67
100th		 67
IS risk (safety) 100 65
62nd		 80
IS quality 86 49
93rd		 49
IS balance sheet 82 50
77th		 55
IS earnings quality 73 56
73rd		 56
IS cash flow 47 32
60th		 41
Piotroski F-score (0-9) 9 6
95th		 5
Altman Z-score 5.8 3.0
68th		 3.2
Beneish M-score −2.45 −2.67
79th		 −2.62
Ohlson O-score −8.31 −7.26
37th		 −7.16
IS credit score 87 62
80th		 62

Per share

MeasurePODDIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $5.41 −$0.07
92nd		 −$0.03
Book value per share $20.49 $10.13
73rd		 $7.10
Tangible book per share $18.12 $2.24
90th		 $1.91
Revenue per share $44.00 $12.68
85th		 $9.38
FCF per share $4.30 $0.62
80th		 $0.46
Operating cash flow per share $7.37 $1.25
90th		 $0.93
Cash per share $7.71 $2.47
83rd		 $3.51

Size (TTM)

MeasurePODDIndustry medianIndustry percentileSector median
Market cap $9.8B $1.6B
80th		 $2.4B
Revenue $3.1B $815.1M
77th		 $770.2M
EBITDA $663.6M $83.1M
78th		 $56.1M
Net income $375.3M −$7.2M
82nd		 −$3.3M
Free cash flow $298.3M $38.8M
78th		 $41.2M
Total assets $3.2B $1.1B
67th		 $1.3B
Shareholders' equity $1.4B $496.6M
68th		 $568.4M
Employees 5,400 1,800
70th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-10-01Pease Flavia
EVP & CFO
 Tax withholding 1,882$130.79$246,14717,357
2026-09-30Mazelsky Jonathan Jay
Director
 Award / grant 141$130.47$18,3961,496
2026-09-30Huffines Robert Luther
Director
 Award / grant 178$130.47$23,2242,627
2026-08-21Mcevoy Ashley
Director, President and CEO
 Open-market buy 1,100$147.47$162,21723,731
2026-08-01Davis Lisa Blair
SVP, Chief HR Officer
 Tax withholding 244$165.35$40,3454,453
2026-07-01Mazelsky Jonathan Jay
Director
 Award / grant 1,355——1,355
2026-06-30Huffines Robert Luther
Director
 Award / grant 151$152.25$22,9902,449
2026-06-30Huffines Robert Luther
Director
 Award / grant 144$159.79$23,0102,442
2026-06-03Stonesifer Timothy C.
Director
 Open-market buy 2,790$143.51$400,3939,041
2026-06-03Borio Luciana
Director
 Open-market sale 418$143.27$59,8874,329
2026-05-20Frederick Wayne A.I.
Director
 Award / grant 1,660——3,818
2026-05-20Borio Luciana
Director
 Award / grant 1,660——4,747

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarAprMayJunJulAugSepOct

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired1315,249$87,619
Open-market buyAcquired23,890$562,610
Open-market saleDisposed1418$59,887
Tax withholdingDisposed33,537$496,505
—Disposed10—
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

12 months: 4 notices · 9,050 shares · $2.9M
FiledFilerShares proposedEst. proceeds
2026-06-03Borio Luciana418$59,885
2025-12-15Frederick Wayne A.I.1,851$542,500
2025-11-26Manea Dan4,475$1.5M
2025-11-24Manea Dan2,306$786,228
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 8 trades (3 purchases) · Senate 0 (0 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-09-25Ro KhannaHouseSale$1,001 - $15,0002026-10-09
2026-09-18Gilbert CisnerosHouseSale$1,001 - $15,0002026-10-13
2026-09-18Gilbert CisnerosHouseSale (Partial)$1,001 - $15,0002026-10-12
2026-09-11Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2024-04-04Tina SmithSenateSale (Partial)$50,001 - $100,0002024-04-19
2024-04-04Tina SmithSenateSale (Partial)$50,001 - $100,0002024-04-18
2024-01-04Markwayne MullinSenateSale$1,001 - $15,0002025-08-13
2024-01-04Markwayne MullinSenateSale (Full)$1,001 - $15,0002025-08-12
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
BlackRock, Inc.6,690,192$1.0B9.65%
VANGUARD CAPITAL MANAGEMENT LLC4,525,333$689.0M6.52%
STATE STREET CORP3,197,555$486.8M4.61%
VANGUARD PORTFOLIO MANAGEMENT LLC3,075,932$468.3M4.44%
BAILLIE GIFFORD & CO2,042,313$310.9M2.94%
GEODE CAPITAL MANAGEMENT, LLC2,003,861$304.0M2.89%
TWO SIGMA INVESTMENTS, LP1,903,734$289.8M2.74%
Invesco Ltd.1,694,651$258.0M2.44%
T. Rowe Price Investment Management, Inc.1,512,160$230.2M2.18%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1,471,069$224.0M2.12%
Clearbridge Investments, LLC1,319,381$200.9M1.90%
MORGAN STANLEY1,268,693$193.2M1.83%
Soleus Capital Management, L.P.1,049,000$159.7M1.51%
NORGES BANK1,047,986$159.6M1.51%
JUPITER ASSET MANAGEMENT LTD1,026,691$156.3M1.48%

Institutional ownership by quarter

2023-092026-06103.9%
% of shares held by 13F filers
2023-092026-06729
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-30729103.9%91330251138
2026-03-31785100.0%88326268121
2025-12-31832101.2%12532726787
2025-09-3081098.3%10734124283
2025-06-30796101.0%14030026850
2025-03-31716103.5%9629722448
2024-12-31682103.1%13024522453
2024-09-30620103.5%9322523166
2024-06-30599100.6%11123419564
2024-03-31562100.7%86224180104
2023-12-31589101.7%14520719372
2023-09-30525101.1%81202188126

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-08-06SCHEDULE 13G/AAbigail P. Johnson1.4%964,297
2026-05-14SCHEDULE 13G/ACapital Research Global Investors2.4%1,669,556
2026-05-06SCHEDULE 13G/AAbigail P. Johnson5.6%3,963,512
2026-04-30SCHEDULE 13GVanguard Capital Management7.5%5,277,842
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.01%$287.6M
VSMPX0.01%$287.6M
VTI0.01%$287.6M
VTSAX0.01%$287.6M
VOO0.01%$237.6M
VFINX0.01%$237.6M

Share structure

Shares outstanding69,354,197
Float69,052,024
Free float99.6%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$1.1B$1.3B$1.7B$2.1B$2.7B
Cost of revenue$346.7M$499.7M$537.2M$625.9M$768.2M
Gross profit$752.1M$805.6M$1.2B$1.4B$1.9B
R&D$160.1M$180.2M$205.0M$219.6M$301.1M
SG&A$466.0M$587.8M$734.9M$917.2M$1.2B
Operating income$126.0M$37.6M$220.0M$308.9M$473.8M
EBITDA$139.6M$109.0M$323.6M$423.7M$586.9M
Pretax income$20.5M$9.8M$214.6M$300.2M$339.5M
Income tax$3.7M$5.2M$8.3M−$118.1M$92.4M
Net income$16.8M$4.6M$206.3M$418.3M$247.1M
EPS, diluted$0.25$0.07$2.94$5.78$3.48
Diluted shares68.6M69.9M73.6M73.9M71.9M

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$791.6M$674.7M$704.2M$953.4M$716.1M
Receivables$161.0M$205.6M$359.7M$365.5M$516.9M
Inventory$303.2M$346.8M$402.6M$430.4M$452.6M
Total current assets$1.3B$1.3B$1.6B$1.9B$1.9B
PP&E, net$546.4M$625.9M$692.8M$759.8M$863.2M
Goodwill & intangibles$76.4M$127.2M$150.4M$150.0M$168.7M
Total assets$2.0B$2.3B$2.6B$3.1B$3.2B
Accounts payable$37.7M$30.8M$19.2M$19.8M$75.0M
Total current liabilities$228.8M$364.7M$451.2M$528.4M$680.1M
Long-term debt$1.2B$1.4B$1.4B$1.3B$979.7M
Total liabilities$1.5B$1.8B$1.9B$1.9B$1.7B
Shareholders' equity$556.3M$476.4M$732.7M$1.2B$1.5B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$16.8M$4.6M$206.3M$418.3M$247.1M
Depreciation & amortization$57.4M$63.2M$72.8M$80.8M$90.4M
Stock-based compensation$34.4M$40.9M$48.3M$69.3M$62.7M
Change in working capital−$263.6M−$2.5M−$190.6M−$17.0M−$23.1M
Operating cash flow−$68.1M$119.0M$145.7M$430.3M$569.3M
Capital expenditure−$122.7M−$157.3M−$75.6M−$124.9M−$191.6M
Free cash flow−$190.8M−$38.3M$70.1M$305.4M$377.7M
Investing cash flow−$82.7M−$191.1M−$119.4M−$146.2M−$222.7M
Net debt issued / repaid$49.4M−$39.8M−$27.0M−$40.6M−$708.1M
Buybacks$0$0$0$0−$59.6M
Dividends paid$0$0$0$0$0

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin68.4%61.7%68.3%69.8%71.6%
Operating margin11.5%2.9%13.0%14.9%17.5%
Net margin1.6%0.4%12.2%20.2%9.1%
FCF margin-17.4%-2.9%4.1%14.1%13.9%
ROE3.0%0.9%34.1%43.0%18.1%
ROIC10.2%1.4%14.3%25.6%18.7%
ROA0.9%0.2%8.5%14.7%7.9%
Debt / equity2.313.011.981.170.69
Interest coverage1.3x1.2x6.9x8.0x6.3x
Current ratio5.753.563.473.542.78
Revenue growth+21.5%+18.8%+30.0%+22.1%+30.7%
EPS growth+141.7%−73.6%+4,395.1%+91.2%−38.1%
P/E at year end1,067.6x4,481.1x73.5x46.2x81.3x
EV / EBITDA at year end140.1x201.0x49.1x46.8x40.8x
FCF yield at year end-1.03%-0.19%0.46%1.51%1.88%
Dividend payout0.0%0.0%0.0%0.0%0.0%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
International Omnipod$1.0B$1.2B$1.7B$2.0B$2.7B
Drug Delivery$87.4M$57.5M$36.0M$38.9M$34.1M

Revenue by region · FY2025

UNITED STATES$2.0B · 72%
Non-US$754.3M · 28%

Street estimates by fiscal year

Next report 2026-11-04 · consensus EPS $1.59 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$3.3B$3.2B – $3.3B$6.51$6.45 – $6.551521.7x
2027$3.7B$3.5B – $3.9B$7.72$7.54 – $8.021518.3x
2028$4.3B$3.8B – $4.6B$9.32$8.78 – $9.811015.1x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-08-05$1.47$1.66+12.9%$787.4M$801.7M+1.8%
2026-05-06$1.19$1.42+19.3%$729.9M$761.7M+4.4%
2026-02-18$1.47$1.55+5.4%$769.0M$783.8M+1.9%
2025-11-06$1.14$1.24+8.8%$678.4M$706.3M+4.1%
2025-08-07$0.92$1.17+27.2%$614.2M$649.1M+5.7%
2025-05-08$0.79$1.02+29.1%$543.3M$569.0M+4.7%
2025-02-20$1.00$1.15+15.0%$582.5M$597.5M+2.6%
2024-11-07$0.76$0.90+18.4%$519.5M$372.6M−28.3%
2024-08-08$0.56$0.55−2.5%$488.0M$488.5M+0.1%
2024-05-09$0.39$0.73+87.2%$424.1M$441.7M+4.2%
2024-02-22$0.66$1.40+112.1%$461.1M$509.8M+10.6%
2023-11-02$0.40$0.71+77.5%$414.4M$432.7M+4.4%
2023-08-08$0.26$0.38+46.2%$384.9M$396.5M+3.0%
2023-05-04$0.09$0.23+155.6%$330.8M$358.1M+8.2%
2023-02-23$0.24$0.55+129.2%$332.4M$369.7M+11.2%
2022-11-03$0.17$0.45+164.7%$312.1M$340.8M+9.2%
2022-08-04$0.21$-0.06−128.6%$291.5M$299.4M+2.7%
2022-05-05$0.23$0.40+73.9%$288.0M$295.4M+2.6%
2022-02-23$0.32$0.42+31.2%$299.3M$307.7M+2.8%
2021-11-04$0.24$0.18−25.0%$272.8M$275.6M+1.0%
2021-08-05$0.12$0.10−16.7%$259.1M$263.2M+1.6%
2021-05-06$0.07$0.01−87.0%$246.2M$252.3M+2.5%
2021-02-23$-0.06$-0.26−333.3%$996.7M$246.1M−75.3%
2020-11-04$0.08$0.17+112.5%$162.9M$234.0M+43.7%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.206-150.306-220.306-290.207-060.507-130.407-200.407-270.808-030.308-100.408-170.308-240.308-31
Week ofNotionalSharesTrades
2026-08-31$318.8M2,149,63852,875
2026-08-24$340.1M2,358,14048,406
2026-08-17$403.0M2,758,74355,372
2026-08-10$295.3M2,055,13757,296
2026-08-03$818.5M5,738,64490,787
2026-07-27$355.1M2,128,32156,273

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1561.7%
DateShort shareShort volumeTotal volume
2026-10-1561.7%360,949585,055
2026-10-1452.1%327,796629,201
2026-10-1350.3%199,541396,497
2026-10-1257.6%318,366552,685
2026-10-0947.4%190,675402,157
2026-10-0848.6%210,936434,073
2026-10-0742.2%178,294422,096
2026-10-0650.9%216,084424,493
2026-10-0539.7%195,624492,452
2026-10-0242.1%171,134406,932
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
+0.0Jan-1.5Feb+0.2Mar+1.8Apr+2.9May+5.0Jun-1.8Jul+8.0Aug-0.2Sep-0.7Oct+7.6Nov+6.0Dec
MonthAvg returnUp yearsYears
Jan+0.0%63%19
Feb−1.5%42%19
Mar+0.2%53%19
Apr+1.8%44%18
May+2.9%47%19
Jun+5.0%68%19
Jul−1.8%37%19
Aug+8.0%79%19
Sep−0.2%47%19
Oct−0.7%58%19
Nov+7.6%68%19
Dec+6.0%47%19
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1455.6
MFI60.1
ADX16.3
Stochastic %K / %D68.6 / 68.0
Williams %R-14.7
CCI153
TSI / signal-6.0 / -14.2
Chaikin money flow0.08
ATR$4.52
Bollinger width9.1%
Volume vs 20-day avg1.01x
SupertrendDown

Moving averages and bands

level (price vs level)
SMA 20$135.67 (+4.0%)
SMA 50$140.43 (+0.5%)
SMA 200$185.76 (−24.0%)
EMA 21$137.17 (+2.9%)
EMA 50$141.51 (−0.3%)
EMA 200$182.13 (−22.5%)
Bollinger upper$141.82 (−0.5%)
Bollinger lower$129.52 (+8.9%)
Parabolic SAR$126.40 (+11.6%)
Open the live chart, 110+ indicators

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

https://www.insulet.com

Key executives

NameTitlePayBorn
Ashley A. McEvoyChief Executive Officer, President & Director$3.1M1971
Eric BenjaminExecutive Vice President & Chief Operating Officer$1.5M1983
Flavia H. PeaseExecutive Vice President & Chief Financial Officer$1.4M1973
John Wodick KapplesSenior Vice President & General Counsel$1.2M1960
Prem SinghSenior Vice President of Global Operations$992,6701977
Amit GulianiSenior Vice President & Chief Technology Officer$954,141—
Chuck MedovichSenior VP and Chief Quality, Regulatory & Compliance Officer——
Clare TrachtmanVice President of Investor Relations——

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Ashley McEvoy President and Chief Executive Officer2025$729,808$13.0M$2.0M$18.9M
James Hollingshead Former President and Chief Executive Officer2025$357,492$8.6M$781,752$13.2M
Flavia Pease Executive Vice President, Chief Financial Officer2025$148,500$3.6M$249,693$5.2M
Eric Benjamin Executive Vice President, Chief Operating Officer2025$596,346$2.2M$893,710$4.5M
Ana Chadwick Former Executive Vice President, Former Chief Financial Officer2025$653,019$2.2M$902,540$4.4M
Mark Field Former Senior Vice President, Chief Technology Officer2025$118,308$1.7M$132,674$3.2M

Employees

1k20181k20192k20202k20213k20223k20234k20245k2025

Dividends

Ex-dateAmountPaid
None on file.

Moat model

Narrow · Cost Advantage · 2026-06-30
Cost advantage76
Intangibles60
Switching costs58
Network effect52
Efficient scale57
Our component scores (0-100) and overall 61.1; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms